Screener
Dianthus Therapeutics DNTH EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Dianthus Therapeutics’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001690585-26-000022
FAQ
- What is Dianthus Therapeutics's EPS (diluted)?
- Dianthus Therapeutics (DNTH) reported EPS (diluted) of -$0.85 in Q1 2026.
- How has Dianthus Therapeutics's EPS (diluted) changed year-over-year?
- Dianthus Therapeutics's EPS (diluted) decreased by 3.7% year-over-year, from -$0.82 to -$0.85.
- What is the long-term trend for Dianthus Therapeutics's EPS (diluted)?
- Over 2 years (2021 to 2024), Dianthus Therapeutics's EPS (diluted) has grown at a 41.7% compound annual growth rate (CAGR), from -$1.30 to -$2.61.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Dianthus Therapeutics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude